{
    "clinical_study": {
        "@rank": "31703", 
        "acronym": "CDGP", 
        "arm_group": [
            {
                "arm_group_label": "Testosterone", 
                "arm_group_type": "Active Comparator", 
                "description": "~1mg/kg every 4 weeks for 6 months"
            }, 
            {
                "arm_group_label": "Letrozole", 
                "arm_group_type": "Active Comparator", 
                "description": "2.5mg daily for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based\n      effective and safe treatment option. This study compares the effects of low-dose\n      testosterone and aromatase inhibitor letrozole on pubertal progression. The hypothesis is\n      that, in boys CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo)\n      induces faster biochemical and clinical progression of puberty as compared to low-dose\n      intramuscular testosterone Rx (~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select\n      watchful waiting instead of medication will provide background data on the natural\n      progression of CDGP, and their data will not be used in primary statistical comparisons."
        }, 
        "brief_title": "Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Constitutional Delay of Growth and Puberty", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Constitutional delay of growth and puberty\n\n          -  Age 14 years or more\n\n          -  mean testicular volume 2.5 ml or more and less than 4 ml\n\n          -  serum testosterone level less than 5 nM OR\n\n        as above, but serum testosterone 1 nM or more with normal DHEAS level, even if the mean\n        testicular volume is less than 2.5 ml\n\n        Exclusion Criteria:\n\n          -  Chronic diseases\n\n          -  Primary or secondary hypogonadism\n\n          -  Chromosomal anomalies\n\n          -  Chronic medication that potentially adversely affects bone mineralization (excluding\n             inhaled corticosteroid treatment)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797718", 
            "org_study_id": "EudraCT:2012-002477-59"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testosterone", 
                "description": "1mg/kg every 4 weeks for 6 months", 
                "intervention_name": "Testosterone", 
                "intervention_type": "Drug", 
                "other_name": "Sustanon 250"
            }, 
            {
                "arm_group_label": "Letrozole", 
                "description": "2.5mg daily for 6 months", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Letrozole Bluefish", 
                    "Letrozole Orion", 
                    "Letrozole Accord", 
                    "Letrozole Sandoz", 
                    "Femar"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone", 
                "Letrozole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Puberty", 
            "Constitutional", 
            "Delay", 
            "Letrozole", 
            "Testosterone"
        ], 
        "lastchanged_date": "March 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "matti.hero@hus.fi", 
                    "last_name": "Matti Hero, MD, PhD", 
                    "phone": "+35894711"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00029"
                    }, 
                    "name": "Helsinki University Central Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuopio", 
                        "country": "Finland", 
                        "zip": "70211"
                    }, 
                    "name": "Kuopio University Central Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Raimo Voutilainen", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Hanna Huopio", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland", 
                        "zip": "20521"
                    }, 
                    "name": "Turku University Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Jorma Toppari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment", 
        "overall_contact": {
            "email": "taneli.raivio@helsinki.fi", 
            "last_name": "Taneli Raivio, MD, PhD", 
            "phone": "+358-9-4711"
        }, 
        "overall_contact_backup": {
            "email": "matti.hero@hus.fi", 
            "last_name": "Matti Hero, MD, PhD", 
            "phone": "+358-9-4711"
        }, 
        "overall_official": [
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "Taneli Raivio, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "Matti Hero, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "Tero Varimo, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "P\u00e4ivi Miettinen, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Turku", 
                "last_name": "Jorma Toppari, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Turku", 
                "last_name": "Harri Niinikoski, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Turku", 
                "last_name": "Kirsi N\u00e4nt\u00f6-Salonen, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Kuopio University Central Hospital", 
                "last_name": "Hanna Huopio, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Finland: National Advisory Board on Health Care Ethics", 
                "Finland: Finnish National Agency for Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Testes will be measured with a ruler to the nearest millimeter and volume will be calculated at 0, 6, and 12 mo", 
                "measure": "testicular volume", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "Activity of the hypothalamic-pituitary-gonadal axis, evaluated by\ngenital and pubic hair stage of puberty according to Tanner;\ngrowth velocity (cm/yr);\nbasal and gonadotropin-releasing hormone (GnRH)-stimulated gonadotropin levels;\nurinary luteinizing hormone levels;\ntestosterone;\ninhibin B;\nanti-mullerian hormone (AMH)", 
                "measure": "clinical and biochemical measures of pubertal progression", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797718"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Helsinki University Central Hospital", 
            "investigator_full_name": "Tero Varimo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Several endpoints related to bone health", 
                "measure": "Bone health", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "Psycho-social well-being will assessed with questionnaires.", 
                "measure": "Psychosocial well-being", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "Biochemical and metabolical changes will be compared btw testosterone and letrozole treatment groups.", 
                "measure": "Puberty-related metabolical and clinical changes", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "Helsinki University Central Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Foundation for Paediatric Research, Finland", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Helsinki University Central Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}